Earth Science Tech Inc. (OTC: ETST) is positioning itself as a vertically integrated healthcare company through its subsidiaries RxCompoundStore, Mister Meds, and Peaks Curative, combining compounding pharmacy, telemedicine, clinical support, and fulfillment capabilities. Its B2B and B2C business model allows the company to serve independent clinics while also selling customized medications directly to consumers, creating diversified revenue streams across physical and digital healthcare operations.
In FY2026, ETST reported revenue of $35.7 million, up from $33.1 million in FY2025 and $11.95 million in FY2024, while also reporting positive operating cash flow and a stronger balance sheet. The company reduced total liabilities from $3.146 million to $1.928 million, increased assets from $7.066 million to $8.969 million, and fully repaid its long-term debt. ETST says it expects operating cash flow to fund its FY2027 needs without additional dilutive financing, highlighting its strategy of pursuing growth through internally generated cash rather than debt or shareholder dilution.
The significance of these results lies in the company's ability to achieve sustained growth while improving its financial health. The substantial revenue increase, particularly the jump from FY2024 to FY2025, demonstrates the scalability of ETST's integrated healthcare model. By combining telemedicine, compounding pharmacy services, and direct-to-patient fulfillment, the company has created a seamless patient experience that drives both clinic partnerships and direct consumer sales.
Moreover, the reduction in liabilities and the full repayment of long-term debt signal a commitment to financial discipline. The increase in assets further strengthens the company's balance sheet, providing a solid foundation for future expansion. The expectation that operating cash flow will cover FY2027 needs without dilutive financing is particularly important for shareholders, as it mitigates the risk of value erosion through additional share issuance.
ETST's business model also aligns with broader trends in healthcare, where patients increasingly seek convenient, personalized care. The company's ability to offer customized medications through its compounding pharmacy subsidiary, coupled with telemedicine consultations, positions it well to capture a growing market. The B2B component, serving independent clinics, adds a recurring revenue stream that complements direct-to-consumer sales.
For investors, the company's performance suggests a viable path to profitability and sustainable growth. The focus on internal cash generation reduces reliance on external funding, which can be especially attractive in a challenging economic environment. The full article can be viewed at https://nnw.fm/oJY5L. To learn more about Earth Science Tech, visit www.EarthScienceTech.com. The latest news and updates relating to ETST are available in the company's newsroom at https://nnw.fm/ETST.
